|ACUR -- USA Stock|| |
USD 0.40 0.0085 2.08%
VP of Technical Affairs
Dr. Albert W. Brzeczko Ph.D. serves as an Vice President, Technical Affairs of Acura Pharmaceutical Technologies, Inc. since February 2009. From 1999 through 2009, Dr. Brzeczko was Vice President, Global Pharma New Product Development and Pharma Technologies for International Specialty Products, Inc., a contract services group specializing in the development of technologies for the bioenhancement of poorly soluble drugs. Prior to 1999, Dr. Brzeczko held various positions of increasing responsibility in pharmaceutical product development with UPM Pharmaceuticals, Banner Pharmacaps, Mylan Laboratories, and DuPont Merck
Age: 59 VP Since 2009 Ph.D
Brzeczko received a BS degree in biochemistry and a Ph.D. in pharmaceutical sciences from the University of Maryland.
Albert Brzeczko Latest Insider Activity
The company has return on total asset (ROA)
of (14.51) %
which means that it has lost $14.51 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (433.84) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 3.62 M in liabilities with Debt to Equity (D/E) ratio of 226.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Acura Pharmaceuticals has Current Ratio of 1.21 suggesting that it is in a questionable position to pay out its financial obligations when they are due.
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products to address medication abuse and misuse. The company was founded in 1935 and is based in Palatine, Illinois. Acura Pharmaceuticals operates under Drug Delivery classification in USA and traded on OTC Market. It employs 15 people.Acura Pharmaceuticals (ACUR) is traded on OTC Market in USA. It is located in ILLINOIS, U.S.A and employs 15 people. Acura Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Acura Pharmaceuticals Leadership Team
|George Ross, Director|
|Robert Jones, CEO|
|Bruce Wesson, Director|
|Peter Clemens, CFO|
|Albert Brzeczko, VP, Ph.D|
|Immanuel Thangaraj, Director|
|James Emigh, President|
|Robert Seiser, VP|
|Bradley Rivet, VP|
|William Skelly, Director|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on Acura Pharmaceuticals. What is your sentiment towards investing in Acura Pharmaceuticals? Are you bullish or bearish?
and pair trading evaluation for Acura Pharmaceuticals and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return